However, when association between methylation status of EBF1 promoter and survival analysis was determined with the Kaplan-Meier method and log-rank test, the patients with CCA exhibiting high EBF1 methylation status is associated with poor prognosis (P = 0.023), as shown in Figure 2D. The overall median survival time was 256 days (95% confidence interval [CI], 221.3-300.7). This evidence concerns the gene EBF1 and cholangiocarcinoma.